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found urinary excretion of pentosidine was increased ca. twofold in patients with MA, compared to 








the basis for identifying patients at risk of early decline in renal function to target and intensify 
renoprotective treatment.
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) and severely decreases likelihood of 
long-term survival of patients with  diabetes1. It has high occurrence linked to a high global prevalence of diabetes, 
5% type 1 diabetes mellitus (T1DM) and 95% type 2 diabetes mellitus (T2DM), with ca. 40% of patients with 
diabetes developing diabetic  nephropathy2,3. Approximately half of patients with diabetic nephropathy progress 
to diabetic kidney disease and ESRD with increased risk of potentially fatal cardiovascular disease. Current 
treatment guidelines address modifiable risk factors through intensification of control of glycemic status, blood 
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pressure and  lipids4. This targets prevention of development of overt proteinuria and decline of GFR to ESRD. 
The effectiveness of current treatments achieves only slowing of decline in GFR. There is also high on-treatment 
mortality, mostly from fatal cardiovascular  disease5. Recent advances have been made through benefits found 
from treatment with inhibitors of sodium–glucose cotransporter 2 (SGLT2)6. Early diagnosis of patients at high 
risk of rapid decline of renal function and intensive management with SGLT2 inhibitors and other therapy may 
improve treatment outcomes. There is an urgent need for biomarkers capable of predicting early GFR decline for 
targeted intensive therapy and to improve understanding of the mechanisms involved in renal injury to guide 
development of more effective renoprotective agents.
Multiple mechanisms of metabolic dysfunction have been proposed to explain the link of diabetic nephropa-
thy to glycemic control. One is the increased formation and accumulation of advanced glycation endproducts 
(AGEs). AGEs are formed by the degradation of fructosamine adducts, such as  Nε-fructosyl-lysine (FL), of 
glucose-modified proteins and by the direct modification of proteins by reactive dicarbonyl metabolites, such 
as methylglyoxal. Examples of major AGEs quantitatively found in the clinical setting are: hydroimidazolone, 
MG-H1—formed by modification of arginine residues with methylglyoxal; and  Nε-carboxymethyl-lysine (CML) 
– formed mainly by the oxidative degradation of FL residues. There is also a minor, trace level AGE protein 
crosslink with intense fluorescence called pentosidine, formed by the reaction of pentose metabolites with spa-
tially close arginine and lysine residues. Protein glycation adducts exist in mainly two forms: glycation adduct 
residues of proteins – sometimes called “protein-bound” glycation adducts, and glycation free adducts or gly-
cated amino acids. Glycation free adducts are formed mostly from proteolysis of endogenous glycated proteins 
with also a contribution from digestion of glycated proteins in food – as recently  reviewed7. AGEs have long 
been considered as risk predictors of diabetic nephropathy and other microvascular complications of  diabetes8. 
Analysis of skin collagen in patients with T1DM showed that a combination of AGEs and the FL-linked analyte, 
furosine, was linked to risk of progression of diabetic  nephropathy9. A blood and/or urine-based biomarker 
would provide more convenient clinical sampling for risk prediction of nephropathy progression. Exploring 
this, plasma protein content of CML was examined and found to be not linked to the risk of developing diabetic 
 nephropathy10. In patients with T1DM and normoalbuminuria (NA), plasma MG-H1 free adduct concentra-
tion was an independent risk predictor for increased thickening of glomerular basement membrane measured 
in renal biopsies, linked to early stage development of diabetes  nephropathy11. Oxidative stress has also been 
implicated in the development of diabetic nephropathy through increased oxidative damage to renal proteins, 
including formation of the protein nitration adduct, 3-nitrotyrosine (3-NT)12. Protein glycation and oxidative 
damage of multiple chemically-defined types may be quantified robustly and concurrently by stable isotopic dilu-
tion analysis liquid chromatography-tandem mass spectrometry (LC–MS/MS)13. In a previous study of patients 
with T1DM, we found changes in serum protein glycation adducts, related serum free adducts and also protein 
oxidation and nitration adduct levels between patients with NA and new onset microalbuminuria (MA) but no 
difference between patients with MA with later stable or declining renal  function14.
Glycated, oxidized and nitrated amino acids have molecular mass < 500 Da. They pass readily through the 
glomerular filter and are excreted in  urine15. Plasma levels vary from 1 – 500 nM and urinary concentrations 
from 10 nM to 100 µM with chemical half-lives ranging from 2 weeks (hydroimidazolone MG-H1) to many years 
(CML) under physiological  conditions13,15,16. The low level of glycation, oxidation and nitration free adducts is 
due to the low in situ rate of protein glycation, oxidation and nitration. Protein glycation by reactive dicarbonyls 
is suppressed by enzymes such as glyoxalase 1 and aldoketo  reductases17 and protein oxidation and nitration is 
suppressed by  antioxidants13. Levels of FL are suppressed by repair of this glycation adduct catalyzed by fruc-
tosamine-3-phosphokinase18. They have different and characteristic renal clearances due to differential reuptake 
in renal  tubules16. We hypothesised that renal handling of glycation, oxidation and nitration free adducts, as 
judged by fractional excretion, may be sensitive to early decline in renal function and thereby a biomarker of 
subsequent decline in renal function. In this study we investigated urinary excretion and fractional excretion of 
glycation, oxidation and nitration free adducts as indicators of their total exposure and relative renal clearance, 
respectively. The outcome suggests fractional excretion of 6 lysine and arginine-derived glycation adducts are 
potential biomarkers for early GFR decline in T1DM and MA.
Results
clinical characteristics of diabetic patients in this study. Eighty-five patients with T1DM were 
recruited for this study. The baseline clinical characteristics are given in Table 1. Thirty patients had NA and 55 
had MA. Of the 55 patients with MA, 22 had early decline in GFR, defined as a decline in GFR > 3.2% per year, 
and the remaining 33 had stable GFR. All 30 patients with NA had stable GFR. In statistical comparisons, com-
paring patients with MA (with and without early decline in GFR combined) to patients with NA, patients with 
MA had a younger age, a higher percentage of current smokers, higher glycated hemoglobin A1c, serum cystatin 
C and, by definition, urinary albumin excretion. Comparing patients with MA and early GFR decline to patients 
with stable GFR with and without MA combined, patients with early decline in GFR had a higher percentage of 
current smokers, higher glycated hemoglobin A1c, plasma total cholesterol and triglycerides, urinary albumin 
excretion and serum cystatin C, and lower  GFRCYSTATIN C.
Urinary excretion of protein glycation, oxidation and nitration free adducts.  We present data 
of urinary excretion of protein glycation, oxidation and nitration free adducts in the patient study groups at 
baseline—Table 2. In the normoalbuminuria patient study group, the urinary excretion of glycation adducts 
was in the approximate order: MG-H1 > FL > CML > CMA ≈3DG-H≈CEL > MOLD > GOLD > pentosidine. The 
urinary excretion of oxidation and nitration adducts was in the approximate order: MetSO > NFK > DT > 3-NT. 
The urinary excretion of protein glycation, oxidation and nitration free adducts between patient study groups 
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with and without MA and early GFR decline was remarkably similar. Only urinary excretion of pentosidine 
free adduct was significant between study groups (P < 0.001, Kruskal–Wallis test). Nevertheless, patients with 
MA with and without early GFR decline had higher urinary excretion of pentosidine, compared to patients 
with NA (0.0442 vs 0.0103 nmol/mg creatinine, P < 0.001); and patients with early decline in GFR had higher 
urinary excretion of pentosidine, compared to patients with stable renal function with and without MA (0.0561 
vs 0.0176, P < 0.01)—Fig. 1.
Fractional  excretion  of  protein  glycation,  oxidation  and  nitration  free  adducts.  Fractional 
excretion of protein glycation, oxidation and nitration free adducts were deduced from the concentrations of 
these analytes in serum, described  previously14, urinary fluxes presented herein and creatinine concentrations 
in serum and urine—Table 3. In patients with normoalbuminuria there was a wide range of fractional excretion 
values of protein glycation, oxidation and nitration free adducts, ranging from 0.8% for MetSO to 100% for FL. 
Patients with MA with and without early function decline had decreased fractional excretion of G-H1 (14.5 vs 
30.7%, P < 0.01) and increased fractional excretion of CMA (22.4 vs 4.3%, P < 0.001) and pentosidine (97.1 vs 
8.8%, P < 0.001), compared to patients with NA. Patients with early decline in GFR had higher fractional excre-
Table 1.  Baseline clinical characteristics of patients in this study. Data are mean ± SD or median 
[interquartile range]. All participants in the normoalbuminuria group had stable GFR. Abbreviations: 
NA, normoalbuminuria group; MA, microalbuminuria group. *These values represent the mean values 
for all measurements taken during the two-year baseline interval used for classification of new onset 
microalbuminuria.
Characteristic Normoalbuminuria (n = 30)
Microalbuminuria (n = 55)
P value NA vs. MA
P value NA and stable GFR vs. 
early GFR declineStable GFR (n = 33) Early GFR Decline (n = 22)
Gender (female, %) 18 (60%) 16 (48%) 13 (59%)
Age (years) 41.9 ± 6.2 36.3 ± 8.8 37.8 ± 8.0  < 0.01
Duration of diabetes (years) 26.3 ± 8.3 23.0 ± 8.2 23.6 ± 8.3
Current smoking (%) 1 (3%) 13 (39%) 11 (50%)  < 0.001  < 0.001
Systolic blood pressure (mmHg) 118.4 ± 11.0 121.6 ± 14.9 128.3 ± 20.1
Diastolic blood pressure (mmHg) 73.4 ± 6.2 76.0 ± 10.5 76.6 ± 8.7
Glycated hemoglobin A1c (%)* 7.81 ± 1.25 8.73 ± 1.10 9.92 ± 1.48  < 0.001  < 0.001
Total cholesterol (mg/dL)* 190 ± 34 187 ± 40 223 ± 39  < 0.001
Triglycerides (mg/dL)* 107 ± 97 97 ± 56 157 ± 117 0.01
Urinary albumin excretion rate (µg/min)*
2-year baseline interval 11.9 [9.7–12.3] 45.1 [32.4–58.2] 47.1 [32.8–55.1]  < 0.001
At time of adduct measurement 6.4 [3.4–13.6] 74.3 [35.2–66.8] 59.8 [36.5–85.5]  < 0.001  < 0.001
Serum cystatin C (mg/L) 0.72 ± 0.08 0.77 ± 0.13 0.85 ± 0.27  < 0.05  < 0.01
GFRCYSTATIN C (ml/min/1.73m2) 117.1 ± 13.6 111.9 ± 18.3 104.6 ± 25.8  < 0.05
Table 2.  Urinary excretion of glycation, oxidation and nitration free adducts (nmol/mg creatinine). Data are 
median [interquartile range]. *A Bonferroni correction of 14 was applied. Data from 3 patients are missing (2 
from MA with stable renal function and one from MA with early decline in renal function).
Urinary free adduct Normoalbuminuria (n = 30)
Microalbuminuria (n = 55)
P value NA vs. MA*
P value NA and stable GFR vs. early 
GFR decline*Stable GFR (n = 33) Early GFR decline (n = 22)
FL 32.0 [22.3–42.3] 37.5 [13.5–71.7] 60.6 [30.9–99.4]
CML 3.30 [2.33–4.70] 2.63 [1.11–5.94] 4.04 [2.87–8.45]
CEL 1.22 [0.90–1.61] 1.06 [0.42–2.53] 1.80 [1.18–3.29]
G-H1 1.92 [1.29–2.39] 1.42 [0.42–2.99] 1.78 [1.33–2.64]
MG-H1 61.9 [30.4–92.3] 42.7 [13.0–93.1] 51.9 [29.2–155.3]
3DG-H 1.34 [1.04–1.94] 0.80 [0.39–1.65] 1.42 [0.74–1.95]
CMA 1.61 [1.25–2.24] 1.70 [0.66–3.66] 2.04 [1.36–4.03]
GOLD 0.0126 [0.0092–0.0207] 0.0189 [0.0057–0.0243] 0.0204 [0.0101–0.0249]
MOLD 0.069 [0.050–0.107] 0.097 [0.065–0.139] 0.109 [0.076–0.158]
Pentosidine 0.0102 [0.0064–0.0170] 0.0313 [0.0144–0.0905] 0.0561 [0.0273–0.1027]  < 0.0001  < 0.01
MetSO 1.12 [0.56–1.93] 0.83 [0.44–1.64] 0.60 [0.30–1.20]
DT 0.0529 [0.0404–0.0639] 0.0325 [0.0175–0.1036] 0.0547 [0.0392–0.0950]
NFK 0.285 [0.205–0.352] 0.138 [0.042–0.320] 0.189 [0.077–0.282]
3-NT 0.0094 [0.0041–0.0169] 0.0136 [0.0045–0.0301] 0.0117 [0.0050–0.0369]
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tion of 6 lysine and arginine-derived glycation adducts, compared to patients with stable function. Glycation 
adducts with higher fractional excretion were: FL, CML, CEL and MG-H1—all increased ca. twofold; and CMA 
and pentosidine, increased ca. sixfold and fivefold, respectively—Table 2. Data distributions of log transformed 
values are given in Fig. 2. There was no similar increase in fractional excretion of unglycated lysine and arginine 
in early GFR decline: lysine, stable GFR 0.41 [0.27–0.75]%, early decline in GFR 0.40 [0.28–0.67]%; and arginine, 
stable GFR 0.51 [0.21–0.83], early decline in GFR 0.39 [0.22–0.65].
correlation analysis. We explored correlations of clinical parameters and the urinary excretion and frac-
tional excretion of protein glycation, oxidation and nitration free adducts for all study group patients combined 
(applying Bonferroni corrections of 14 and 12 respectively; P < 0.05). For urinary excretion of free adducts, 
we found that total plasma cholesterol was positively correlated with urinary excretion of FL (r = 0.32), CML 
(r = 0.34), and CEL (r = 0.31). Patient age was positively correlated with urinary excretion of NFK (r = 0.33). 
Diabetes duration was positively correlated with urinary excretion of NFK (r = 0.36). In addition, female sex 
was associated with higher urinary excretion of GOLD (0.0107 versus 0.0193 nmol/mg creatinine). For frac-
tional excretion, there were positive correlations of glycated hemoglobin A1c with fractional excretions of CML 
(r = 0.42) and CEL (r = 0.36), and total plasma cholesterol with fractional excretion of CML (r = 0.34). Diabetes 
Figure 1.  Urinary excretion of pentosidine in cases of new onset microalbuminuria with and without Early 
GFR decline compared to normoalbuminuria controls. (a) Increased urinary excretion of pentosidine in 
patients with MA, with respect to patients with NA. (b) Increased urinary excretion of pentosidine in patients 
with early decline in GFR, with respect to patients with stable renal function. Data distributions are shown with 
horizontal bars indicating median values. Statistical analysis: Mann–Whitney U test.
Table 3.  Fractional Excretion of Protein Glycation, Oxidation and Nitration Free Adducts (%). Data are 
median [interquartile range]. Statistical analysis was performed using the Student’s t-test of log-transformed 
values. *Significance of difference remained significant after a Bonferroni correction of 12 was applied. Data 
from 3 patients are missing (2 from MA with stable renal function and one from MA with early decline in 





(n = 55) P value (NA vs MA)
NA and stable GFR 
(n = 63)
Early GFR decline 
(n = 22)
P value stable vs early 
GFR decline
FL 100 [54–160] 153 [79–247] 100 [58–204] 204 [114–257]  < 0.05
CML 30.4 [25.0–39.4] 43.6 [22.1–71.9] 30.6 [21.7–43.5] 52.3 [44.8–81.9]  < 0.01*
CEL 26.4 [16.0–33.7] 28.3 [18.1–52.9] 25.1 [12.6–34.4] 42.4 [26.0–52.0]  < 0.05
G-H1 30.7 [15.0–60.0] 14.5 [5.3–30.0]  < 0.01* 19.6 [6.9–39.6] 17.9 [13.4–44.1]
MG-H1 113 [91 -146] 123 [73–263] 111 [71–156] 182 [115–290]  < 0.05
3DG-H 15.0 [11.6–23.5] 15.8 [8.4–27.9] 14.0 [8.9–22.7] 19.8 [14.1–39.9]
CMA 4.3 [2.9–5.6] 22.4 [7.2–57.5]  < 0.001* 6.0 [3.9–23.6] 32.2 [7.6–89.6]  < 0.001*
Pentosidine 8.8 [5.0–20.3] 97.1 [38.2–141.1]  < 0.001* 20.9 [7.3–94.9] 109.1 [74.6–143.8]  < 0.001*
ΣERFD predictors 285 [223–387] 537 [293–867]  < 0.05* 337 [217–526] 785 [499–991]  < 0.001*
MetSO 0.8 [0.3–1.6] 0.6 [0.4–1.3] 0.7 [0.3–1.5] 0.6 [0.4–1.4]
DT 26.7 [20.9–43.8] 27.8 [12.5–56.8] 26.6 [15.6–50.6] 29.4 [19.0–49.7]
NFK 8.8 [5.7–14.3] 6.6 [2.6–10.7] 7.7 [3.5–11.0] 9.2 [3.7–12.1]
3-NT 10.5 [4.2–29.4] 13.4 [5.7–26.6] 13.3 [4.6–26.5] 11.8 [7.7–30.5]
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duration was positively correlated with fractional excretion of NFK (r = 0.32). Blood pressure and current smok-
ing status were not associated with any of the adducts.
We also studied correlation of the flux of urinary free adducts at baseline with GFR CYSTATIN C, urinary albumin 
excretion rate (AER) and slope of future decline in GFR (%/year). There were no significant correlation of urinary 
protein glycation, oxidation and nitration adduct with GFR CYSTATIN C. For AER, there was a positive correlation 
with urinary excretion of pentosidine (r = 0.43, P < 0.001). We found future rate of decline in GFR correlated 
negatively with urinary CEL (r =− 0.35, P < 0.01) and urinary pentosidine (r =− 0.42, P < 0.001). This may suggest 
Figure 2.  Fractional excretion of glycation free adducts in cases of new onset microalbuminuria with and 
without early GFR decline compared to normoalbuminuria controls. Increased fractional excretion (FE) of 
glycation free adducts in patients with early decline in GFR, with respect to patients with stable renal function. 
Data are log(FEglycation adduct/%). Panel key: (a) FL. (b) CML. (c) CEL. (d) MG-H1. (e) CMA. (f) Pentosidine. 




Scientific RepoRtS |        (2020) 10:12709  | https://doi.org/10.1038/s41598-020-69350-y
www.nature.com/scientificreports/
that for patients with diabetic nephropathy, future early decline in renal function is linked to increased exposure 
to the glycating agent, methylglyoxal, and increase pentosephosphate pathway metabolism leading to increased 
formation of pentosidine. Future rate of decline in GFR correlated negatively with fractional excretion of CML 
(r =− 0.41, P < 0.01), CEL (r =− 0.36, P < 0.05), MG-H1 (r =− 0.37, P < 0.05), 3DG-H (r =− 0.36, P < 0.05), CMA 
(r =− 0.36, P < 0.05) and pentosidine (r =− 0.41, P < 0.01).
Discussion
In this study we present for the first-time evidence that fractional excretions of 6 lysine and arginine-derived 
glycation adducts are higher in patients with T1DM and early decline in GFR, compared to patients with T1DM 
and stable renal function with or without MA. This suggests that fractional excretion of these glycation free 
adducts (glycated amino acids) may be a risk predictor of subsequent rapid decline in renal function. This is of 
interest to validate in a future study and independent cohort, including in patients with type 2 diabetes mellitus. 
If validated, the measurement of these analytes is simple and could provide the basis for identifying patients at 
risk of early decline in renal function to target and intensify renoprotective treatment. Fractional excretion may 
be further affected by weight, age and gender, although these are generally rather considered linked to urinary 
flux of creatinine and not to the specific  analytes19,20.
Protein glycation, oxidation and nitration are endogenous spontaneous processes occurring in healthy sub-
jects. The in situ rates of protein glycation, oxidation and nitration are increased in patients with T1DM. Relat-
edly, there are increased levels of protein glycation, oxidation and nitration free adducts in plasma and urine of 
patients with T1DM, compared to healthy  controls16. The flux of formation of protein glycation, oxidation and 
nitration free adducts in patients with T1DM with and without early renal function decline, as judged by the 
urinary flux of free adducts, was unchanged—except for increase of pentosidine in early renal function decline. 
The observed higher fractional excretion of glycation free adducts is likely an indicator of decline in renal func-
tion and more sensitive to early renal function decline than serum creatinine or cystatin C. As glycation free 
adducts analytes pass readily through the glomerular filter, this effect is likely due to decreased tubular reuptake 
of glycation free adducts. Related increased renal clearance of glycation free adducts in stable renal function was 
found previously in streptozotocin-induced diabetic rats with albuminuria and stable renal  function21. We also 
found higher renal clearance of glycation free adducts in patients with T1DM with normal renal function, com-
pared to healthy  controls16. For FL there may also be lower renal metabolism by fructosamine 3-phosphokinase 
associated with decreased reuptake by the tubular  epithelium22. Pentosidine also undergoes tubular reuptake and 
metabolism in the kidney and this may also be susceptible to decrease in the setting of early decline of  GFR23. 
Increased fractional excretion of multiple lysine and arginine-derived glycation adducts was found, suggesting 
that the effect is not linked to a particular glycation process. Rather, the higher fractional excretions are likely 
indicative of change in activity of transport proteins mediating reuptake of glycation free adducts in the tubular 
epithelium. Lysine and arginine-derived glycation free adducts are thought to be taken up and moved across the 
tubular epithelium by low affinity binding to cation transporter proteins which also take up arginine and lysine, 
heterodimeric complex  b0,+AT/rBAT on the apical surface (gene names SLC7A9 and SLC3A1, respectively) and 
Figure 3.  Schematic diagram of amino acid transporters of arginine and lysine uptake in the renal tubular 
epithelium and engagement with glycation free adducts. See Discussion for description.
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CAT-1 and heterodimeric complexes of y + LAT1, y + LAT2 with 4F2hc on the basolateral surface (gene names 
SLC7A1, SLC7A7, SLC7A6 and SLC3A2, respectively)24–28—Fig. 3. Interestingly, CAT-1 is regulated by glucose 
and insulin and may suffer periodic variation in patients with  T1DM29; and in genome-wide association studies 
genetic polymorphism of SLC7A7, SLC7A7 and SLC7A9 was associated with variation in eGFR and develop-
ment of chronic kidney  disease30,31. There was no similar increase in fractional excretion of arginine and lysine. 
This may be because glycation free adducts have markedly low binding affinity to cation transporters and higher 
fractional excretions compared to arginine and  lysine24–26. This weak binding affinity of glycation free adducts 
is expected to confer greater sensitivity to decline in transporter activity than the corresponding unmodified 
amino acids.
In some patients, mostly those with early GFR decline, fractional excretion of FL, MG-H1 and pentosidine 
exceeded 100%; renal clearance of these glycation free adducts was greater than that of creatinine. This is likely 
mediated by high active tubular secretion and may be an indication of the tubular epithelium under physi-
ological stress related to subsequent decline in  GFR32. Active tubular secretion is mediated by organic anion 
transporters (OATs) and organic cation transporters (OCTs) on the basolateral side and multidrug and toxin 
extrusion proteins (MATEs) on the apical side of the tubular  epithelium32. These transporters may also accept 
zwitterionic substrates such as glycation free  adducts33. Increased flux of glycation free adducts and other ionic 
substrates through the tubular epithelium may be an early-stage functional change contributing to subsequent 
decline in renal function.
In contrast, fractional excretion of oxidation free adducts was not associated with MA status and early 
decline in GFR. Fractional excretion of MetSO was very low (< 1%), as expected for the high renal metabolism 
of MetSO by MetSO  reductases34. DT, as a dipeptide-like structure, may have tubular reuptake by peptide trans-
porter protein such as H + –peptide co-transporter  PEPT124, and NFK and 3-NT by the tryptophan and tyrosine 
transporter proteins, respectively—proteins 4F2hc/LAT1 and TAT1 (genes SLC3A2/SLC7A5 and SLC16A10)35. 
These transporter proteins have no known link to chronic kidney disease. No changes of fractional excretion of 
DT, NFK and 3-NT with MA and early decline in GFR were found herein.
Other findings reported herein were urinary excretion rates of glycation, oxidation and nitration free adducts 
in patient study groups. There were remarkably few changes in patient study groups except for increased urinary 
excretion rates of pentosidine. Pentosidine excretion was ca. twofold higher in patients with T1DM and MA, 
compared to patients with T1DM and NA, and also ca. threefold higher in patients with early decline in GFR, 
compared to patients with stable renal function. Pentosidine is formed from pentose metabolite precursors and 
is a biomarker of pentosephosphate pathway  activity36. Urinary excretion of pentosidine may reflect increased 
endogenous formation of pentosidine associated with increased pentosephosphate activity sustaining formation 
of NADPH cofactor for aldoketo reductases and glutathione reductase to counter dicarbonyl stress and oxidative 
stress in  diabetes12,37. This may become more marked in MA and early decline in GFR with increased dicarbonyl 
stress and oxidative stress associated with accumulation of renal  toxins38. Decreased renal metabolism of pento-
sidine may also contribute to the increased excretion of pentosidine.
Fractional excretion of the glycation adduct G-H1 was lower and fractional excretions of CMA and pen-
tosidine were higher in patients with MA with and without early GFR decline, compared to patients with NA. 
These effects were maintained when comparing patients with stable renal function with and without MA; that is, 
these changes relate to increased in urinary albumin in the NA to MA range. Impaired tubular reuptake and/or 
metabolism of CMA and pentosidine may be stimulated in response to increased albumin in the tubular lumen 
before decline in GFR begins. These glycation analytes may be particularly sensitive to early dysfunction in the 
glomerular filter and albumin salvage  pathway39.
Patients with T1DM have increased exposure to glycating agents, glucose, methylglyoxal, glyoxal and 3-deoxy-
glucosone linked to insulin deficiency, dysregulated glucose metabolism and  glycolysis40–42. For example, in 
an earlier study plasma glucose was increased two–threefold and whole blood methylglyoxal concentrations 
increased five–sixfold in patients with  T1DM40. Consistent with this, there is increased endogenous glycation of 
proteins with cell proteolysis leading to the increased formation and excretion of glycation free  adducts21. Con-
sequently, urinary excretion of FL and MG-H1 free adducts were increased in patients with T1DM, increases in 
urinary excretion of FL often being less than expected due to metabolism by fructosamine 3-phosphokinase16,22. 
Since hyperglycemia and increased methylglyoxal have been evidenced as mediators of the development of 
diabetic nephropathy in experimental diabetes and linked to progression of clinical diabetic  nephropathy11,43–46, 
it may be surprising that only urinary excretion of pentosidine free adduct was linked to early decline in GFR 
herein. Urinary excretion of glycation free adducts may be more closely associated with later stages of decline 
in GFR. Factors that may likely mask the association of urinary excretion of glycation free adducts to develop-
ment of MA and early decline in GFR are: (i) high variability of the contribution to urinary excretion of major 
glycation free adducts from digested glycated proteins in food, producing increased dispersion of estimates of 
urinary  excretion47; and (ii) urinary excretion of glycation free adducts vary from day-to-day whereas clinical 
development of MA and decline in GFR in patients with T1DM develops slowly over 10–20 year 44,48. Associa-
tion of increased fractional excretion of glycation free adducts, as an in situ measure of renal function likely 
reflecting proximal tubular uptake and active secretion of these metabolites, may be a mechanistic biomarker 
that is little impacted by these factors.
The current clinical biomarker widely used to assess risk of early renal function decline is urinary albumin 
or ACR as reported herein. It is a predictor of decline in renal function but has limited sensitivity and specificity, 
with many patients with normoalbuminuria progressing to early renal function  decline49. Clinical risk factors for 
decline in renal function in diabetic nephropathy include age, diabetes duration,  HbA1c, systolic blood pressure, 
albuminuria, baseline GFR and retinopathy status. From recent studies, potential clinical biomarkers for early 
renal function decline in patients with T1DM and microalbuminuria are: plasma soluble tumor necrosis factor 
receptor isoforms 1 and 2 (TNFR1 and TNFR2) and E-selectin50,51, plasma kininogen and kininogen  fragments52 
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and 7 metabolites identified in an unfocussed metabolomics study (C-glycosyltryptophan, pseudouridine, 
O-sulfotyrosine, N-acetylthreonine, N-acetylserine,  N6-carbamoylthreonyl-adenosine, and  N6-acetyllysine)53. 
Protein glycation, oxidation nitration adducts were not quantified in this metabolomics study. In a study assess-
ing rapid development of diabetic nephropathy by measurment of glomerular basement membrane thickening 
in renal biopsies of patients with T1DM, increased plasma MG-HI, CEL, and CML free adducts were linked to 
rapid progression of diabetic nephropathy in a logistic regression  model11. A further biomarker developed was 
a diagnostic algorithm based on the abundance of 273 urinary peptides (CKD273)54. The latter biomarker has 
been used to risk stratify patients in a clinical  trial55. Useful clinical biomarkers for early renal function decline 
in diabetic nephropathy are those that are readily translated to the clinical chemistry laboratory, reliably and 
rapidly quantified, provide marked diagnostic improvement over current methods and are linked mechanistically 
to early-stage decline in renal function. With further validation, fractional excretion of one or more glycation 
adducts may meet these criteria.
The major limitations of this study are the relatively small size of the patient study groups and, for wider 
application, limited commercial availability of analytical  standards56. In future studies it will be of interest to 
study changes in expression of amino acid transporters implicated in glycation adduct reuptake in renal proximal 
tubules in experimental models of diabetic kidney disease and in renal biopsies of clinical diabetic kidney disease. 
It is also of interest to explore association of genetic polymorphisms of amino acid transporters with early renal 
function decline in diabetic kidney disease.
conclusions
We found higher fractional excretion of 6 lysine and arginine-derived glycation adducts in patients with T1DM 
and MA with early decline in renal function, compared to patients with T1DM with and without MA and stable 
renal function. Higher fractional excretion of glycation free adducts may be an indicator of early functional 
decline of tubular cation transport protein function, known to be linked to chronic kidney disease, and may be 
a valuable biomarker for identification of patients with T1DM at risk of rapid decline in renal function.
Methods
Subject study groups and sampling.  Subject group participants in this study were recruited and enrolled 
in the First Joslin Study of the Natural History of Microalbuminuria in Type 1 Diabetes, a follow-up cohort study 
of patients with T1DM new onset MA initiated in 1991 by the Internal Medicine and Pediatrics departments of 
the Joslin Diabetes Center (Boston, USA). Thereafter, members of the cohort returned to the clinic and random 
urine specimens were examined for MA. Details of the selection criteria and methods were published with the 
results of the screening  study57,58. The protocol and consent procedures were approved by the Committee on 
Human Studies of the Joslin Diabetes Center. Written informed consent was obtained from all participants. The 
study registration number of the Joslin Diabetes Center Committee on Human Studies was: 88–17. The study 
was conducted in accordance with the Declaration of Helsinki on ethical principles for medical research.
From among the 267 patients who had persistent NA during the interval 1991 and 2004, we randomly 
selected 30 patients as a reference group with at least 12 years of follow-up as controls for this study. From the 
109 patients who developed new-onset MA between 1992 and 1996, 86 patients had more than 10 years follow-up 
and we identified 55 of these for whom we had obtained urine and serum specimens during one of the biennial 
examinations carried out between 2000 and 2004. Measurement of urinary albumin-creatinine ratio (ACR) was 
used for both the diagnosis and follow-up of urinary albumin excretion (UAE) of this study. Urinary albumin 
concentration was measured by immune-nephelometry (Behring, Somerville, NJ, USA) and urinary creatinine 
concentration was measured by colorimetry (modified Jaffe reaction) on an Astra-7 automated system (Beckman 
Instruments, Brea, CA, USA)57,58. The patient’s level of UAE was defined according to a consensus of the last three 
measurements; a category of UAE was assigned if the level is confirmed by at least two out of three consecutive 
measurements, imposing time constraints on the intervals between measurements. The lower and upper limits 
of ACR for MA were: for men, 17 and < 250 µg/mg (1.9 and 28 mg/mmol); and for women, 25 and < 355 µg/
mg (2.8 and 40 mg/mmol),  respectively59. In order to detect persistent MA, measurements of ACR be separated 
by ≥ 8 weeks (median interval was 5 months). A fixed interval of two years was used to define the level of UAE 
over which the majority of patients (61%) had at least three ACR determinations.
Participants were also classified according to the presence of “early GFR decline”, determined using longitu-
dinal measurements of glomerular filtration rate estimated by serum cystatin C  (GFRcystatin C), and derived from 
the linear regression of log-transformed values for each individual over 10 or more years of follow-up. Early 
GFR decline was defined as percent change in  GFRcystatin C < -3.2%/year44. Twenty-two participants had early GFR 
decline and 33 had stable GFR. All 30 normoalbuminuric participants had stable GFR.
Baseline height and weight were abstracted from the medical records. BMI was calculated by the formula: 
weight (in kilograms) divided by height (in meters) squared.
Measurement  of  protein  glycation,  oxidation  and  nitration  adducts  in  urine.  As described 
above, urine specimens were obtained within the first 4 years of MA onset (n = 55) and within the first 4 years of 
follow-up in those subjects with normoalbuminuria (n = 30)14. Urine ultrafiltrate was prepared passing an aliquot 
of urine (50 µl) through a 3 kDa microspin ultrafilter at 4 °C (10,000 g, 30 min). Urinary glycation, oxidation 
and nitration free adducts were determined by assay in the ultrafiltrate by stable isotopic dilution analysis liquid 
chromatography-tandem mass spectrometry (LC–MS/MS)—also called AGEomics; pentosidine was measured 
by concurrent fluorescence  detection15. A detailed step-by-step protocol was published  previously60, including 
description and discussion of the method and its strengths and  weaknesses56. Briefly, an aliquot of urine ultra-
filtrate (5 µl) was mixed with a cocktail of stable isotope-substituted internal standard analytes in initial mobile 
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phase (0.1% trifluoracetic acid (TFA) in water), final volume 50 µl, and analysed by LC–MS/MS. For the chroma-
tographic step, the mobile phase was 0.1% TFA in water with a custom multi-step gradient of increasing 0–50% 
acetonitrile; flow rate 0.2 ml/min. Elution was through two columns in series, with column switching to facili-
tate rapid elution of analytes of diverse hydrophobicity. The columns were: 5-µm particle size HYPERCARB; 
column-1, 2.1 × 50 mm and column-2, 2.1 × 250 mm (Thermo Fisher Scientific, Loughborough, U.K.); column 
temperature was 30 °C. Eluate flow from 0–4 min was diverted to waste (containing non-volatile salts) and then 
switched to the mass spectrometer from 4–33 min for data collection. Analytes and stable isotope-substituted 
internal standards were detected by cationic electrospray ionisation (ESI) tandem mass spectrometry in multiple 
reaction monitoring (MRM) mode. The detection response is specific for chromatographic retention time and 
masses of molecular ion and fragment ion. Detection responses were optimised for molecular and fragment 
ion masses (± 0.1 Da), collision energy (± 1 eV) and capillary voltage (± 1 eV), as given  previously60. Samples 
and calibration standards (6 known amounts of authentic standards covering the sample analyte content range 
mixed with stable isotopic standards) were analysed under identical conditions in the same run. The amount of 
analyte in the samples is deduced by interpolating the analyte/stable isotopic standard peak area ratio deduced 
from MRM chromatograms on calibration curves. Calibration curves were linear over the working analyte 
amount with  R2 ≥ 0.993 for all analytes. Pentosidine was detected by in-line fluorescence detection; excitation/
emission wavelengths 320/385 nm. Limits of detection of analytes and other analytic characteristics for analytes 
are given  elsewhere60. The interbatch coefficient of variance of urinary analytes quantified herein was < 5%. In 
total, 12 analytes were measured: FL, CML,  Nε-carboxyethyl-lysine (CEL), glyoxal-derived hydroimidazolone 
(G-H1), MG-H1, 3-deoxyglucosone-derived hydroimidazolones (3DG-H),  Nε-carboxymethyl-arginine (CMA), 
glyoxal and methylglyoxal-derived lysine dimers, GOLD and MOLD, methionine sulfoxide (MetSO), N-formyl-
kynurenine (NFK), dityrosine (DT) and 3-NT. Analyte concentrations were normalised to urinary creatinine 
and combined with previously determined serum concentrations to deduce fractional excretion values. Sample 
analysis was performed in 2007.
Statistical analysis. Baseline clinical characteristics were compared using the Student’s t-test, the Wilcoxon 
rank-sum test, or the χ2-test, and 2 separate comparisons were made: 1) between those with NA (n = 30) and 
MA (n = 55) and 2) between those who demonstrated stable GFR (n = 63) and early GFR decline (n = 22)14. GFR 
measured longitudinally was determined using cystatin C and slopes were subsequently produced by the use of 
a linear model on log-transformed values to obtain percent change over time. To compare urinary excretion of 
glycation, oxidation and nitration free adducts, the Kruskal–Wallis test was applied for the 3 study groups and 
Mann–Whitney U test was applied to compare difference of medians of two study groups. To compare fractional 
excretion data, the Student’s t-test was performed on log-transformed values of the 12 free adducts. Correlation 
analysis was performed using non-parametric Spearman method. An α-level of 0.05 was used for tests of signifi-
cance, and a Bonferroni correction was used for analyses of urinary and fractional excretion. Statistical analysis 
was performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
Data availability
The data used to support the findings of this study are available from the corresponding author upon request.
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